In Crohn's disease, vagus nerve stimulation (VNS) induces an acute cortical activation in low frequency bands. VNS has a slow action on the cortex by progressively reducing power in the alpha frequency band. The VNS induced alpha power decrease is correlated with clinical improvement of Crohn's disease.
i g h l i g h t s
In Crohn's disease, vagus nerve stimulation (VNS) induces an acute cortical activation in low frequency bands. VNS has a slow action on the cortex by progressively reducing power in the alpha frequency band. The VNS induced alpha power decrease is correlated with clinical improvement of Crohn's disease.
a b s t r a c t
Objectives: In the context of the first clinical trial of vagus nerve stimulation (VNS) in Crohn's disease (CD), our main objective was to quantify the acute and chronic effects of VNS on brain activity in CD patients. Methods: We measured the electroencephalogram (EEG) in 9CD patients under VNS at 10 Hz just before VNS initiation, after 6 weeks and after 12 months of chronic VNS. Results: Acute VNS induced increased spectral power in delta and theta bands on frontal, temporal and occipital electrodes. The main significant modulation was the 12 months' chronic effect of VNS which consisted mainly in a decreased power in the alpha frequency band which was correlated with the normalization of bowel mucosal inflammation, anxiety state and vagal tone.
Conclusions: In addition to the activation of vagal efferent fibers that regulate the autonomic nervous system, our data suggest that chronic VNS has a regulatory action via afferent vagal fibers on anxiodepressive symptomatology associated to CD, which could be directly highlighted by the modulation of EEG alpha power known to be associated to depressed states. Significance: This is the first report of the central effects of VNS in CD patients. Ó 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.
Introduction
Crohn's disease (CD) is a chronic inflammatory bowel disease traditionally requiring treatments with important side effects, such as anti-TNF (tumor necrosis factor) therapy, which is efficient only for 30-40% patients who, moreover, can become non-responders later (up to 50% of them) (Olesen et al., 2016) . This therapy can further generate adverse effects like infections and up to half of the CD patients will not continue therapy (non-compliance). Therefore, because vagus nerve stimulation (VNS) is thought to activate the cholinergic anti-inflammatory pathway, an anti-tumor necrosis factor (TNF) pathway partly through the action of acetylcholine 
